Exscientia Seeks Proof of AI Benefits Amid Leadership Changes and Cautious Investor Sentiment
-
Exscientia utilizes AI for drug discovery, but seeks proof that this leads to better outcomes. Recent leadership changes and stock declines have created cautious investor sentiment.
-
Pipeline updates Phase 1 trials progress for cancer drug candidate GTAEXS617; AML drug EXS74539 advances to trials this year; updates soon on MALT1 inhibitor EXS73565.
-
New collaboration with Sanofi utilizing AI platform for up to $345M in milestones, plus royalties.
-
Strong financial position with £366M in cash/deposits, cash runway of 27 months at current burn rate. Market cap $822M.
-
Recommendation shifted from Buy to Hold due to mixed signals. Seeking definitive proof of AI benefits and clinical/market success.